JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Highlights in clinical autonomic neurosciences: Clinical update on multiple system atrophy.

Multiple system atrophy (MSA) may be the most feared of diseases affecting the autonomic nervous system. Accordingly, concerted efforts are underway to elucidate further its pathophysiology with the objective of discovering effective neuroprotective interventions that can slow or halt its progression. Although the epidemiology of MSA is sporadic rather than familial, recently reported associations with COQ2 and C9orf72 suggest that in some cases genetic factors may influence the risk of developing the disease. Research has also identified prion-like characteristics of the expansion of pathologic α-synuclein in the central nervous system. A large clinical trial of rifampicin, which disaggregates and inhibits the formation of α-synuclein fibrils, however, was clearly negative. Other research has shown the importance of recognizing and treating vocal cord paralysis, which is associated with adverse prognosis.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app